|
 Britain's biggest drugmaker is trying to boost low investor
expectations for its product pipeline by hosting its first research
and development day in more than a decade.
The company highlighted advanced and early-stage projects in
respiratory medicine, immunology, oncology, vaccines, HIV and other
infections, and rare diseases.
(Reporting by Ben Hirschler; Editing by Keith Weir)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
